MindMed Board is Trippin': Significant Investor Calls for Termination of Highly Dilutive Equity Offering and Pledges to Hold Board and Management Accountable through Activist Campaign
28 Sep 2022
Investors States Shareholder Requisition of Special Meeting to Effect Significant Change to the Board May be Necessary
SHERIDAN, Wyo., Sept. 28, 2022 /PRNewswire/ -- Today, FCM MM HOLDINGS, LLC ("FCM") announces that it has sent a letter (the "Letter") to the Board of Directors (the "Board") of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) ("MindMed" or the "Company") informing the Board of FCM's vehement opposition to the Company's public offering announced on September 27, 2022 (the "Dilutive Offering"). In the Letter, FCM details how the Board's and management's actions, including the Dilutive Offering, have destroyed shareholder value, calls for the Board to immediately terminate the offering, and pledges to take action to hold the Board accountable.
Continue Reading
"We are committed to taking whatever actions are necessary to protect the interest of shareholders, and we look forward to engaging in a zealous proxy campaign" said FCM Chief Executive Manager Jake Freeman.
"We are committed to taking whatever actions are necessary to protect the interest of shareholders"
Tweet this
The full text of the letter is available and can be downloaded at mindmed.zone/letterdilution
About FCM
FCM is managed by Jake Freeman and represents an investment of 6.1% of MindMed's shares outstanding.
FCM additionally represents other early investors in MindMed, including Scott Freeman and Chad Boulanger, who all have a strong interest in seeing the long-term success of MindMed.
For additional disclosure relating to public broadcast solicitations please see mindmed.zone/disclosure
Media Contact
Jake Freeman
30 N Gould St. Ste R
Sheridan, WY 82801
Phone: 908-308-2381
Email: [email protected]
SOURCE FCM MM Holdings, LLC
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.